ホーム › 非小細胞肺癌 › サウスダコタ › Sioux Falls
Sioux Falls、SDにおける非小細胞肺癌の臨床試験
Sioux Fallsとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Avera Medical Group, Sioux Falls
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
被験者募集中第2相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
被験者募集中第3相
- Sanford Cancer Center ( Site 3266), Sioux Falls
- Avera Cancer Institute ( Site 3209), Sioux Falls
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- Avera Cancer Institute, Sioux Falls
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- Sanford Cancer Center ( Site 0053), Sioux Falls
- Avera Cancer Institute- Research ( Site 0090), Sioux Falls
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Avera Cancer Institute- Research, Sioux Falls
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Sioux Falls
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Sioux Falls
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- Avera Cancer Institute, Sioux Falls
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
被験者募集中観察研究
- Sanford Cancer Center ( Site 0038), Sioux Falls
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
被験者募集中第1/2相
- Sanford Cancer Center ( Site 0038), Sioux Falls
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
被験者募集中第2相
- Sanford Cancer Center ( Site 0038), Sioux Falls
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
被験者募集中第2相
- Sanford Cancer Center, Sioux Falls
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Sioux Fallsにおける他の研究
- 乳がん18件の研究
- 卵巣がん16件の研究
- 肺がん14件の研究
- がん（全種類）13件の研究
- 子宮内膜がん11件の研究
- 転移性癌10件の研究
- 大腸癌9件の研究
- 頭頸部扁平上皮癌9件の研究
- 心不全7件の研究
- 結腸癌7件の研究
- トリプルネガティブ乳がん7件の研究
- 前立腺がん7件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。